In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells

Anti-Cancer Drugs

Volumn 20, Issue 9, 2009, Pages 807-814

  Gao, Chunli ^a   Pan, Jun ^a   Lu, Weiyue ^a   Zhang, Ming ^a   Zhou, Liang ^a   Tian, Jie ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Laryngeal carcinoma; Methoxy poly(ethylene glycol) poly(lactideco glycolide); Nanoparticle; Paclitaxel

Indexed keywords

DRUG CARRIER; METHOXY POLY(ETHYLENE GLYCOL) POLY(LACTIDE CO GLYCOLIDE); NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LARYNX CANCER; LASER MICROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTIC ACID; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 70349137110     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328330c811     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-194.
3. StGuily JL, Brasnu D, Bassot V, Chevalier H, Jacquillat C, Laccourreye H. Induction chemotherapy of cancers of the upper respiratory and digestive tract. Analysis of tumor response in 176 patients. Presse Med 1985; 14:1313-1316.
4. Laccourreye H, Bonfils P, Brasnu D, Menard M, Fabre A, Janot F, et al. Chemotherapy and partial surgery in epithelioma of the pharyngo-larynx. Ann Otolaryngol Chir Cervicofac 1988; 105:409-414. (Pubitemid 18271263)
5. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
6. Laccourreye O, Weinstein G, Brasnu D, Bassot V, Cauchois R, Jouffre V, et al. A clinical trial of continuous cisplatin-fluorouracil induction chemotherapy and supracricoid partial laryngectomy for glottic carcinoma classified as T2. Cancer 1994; 74:2781-2790.
7. Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34:224-228.
8. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091-2098.
9. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active-drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83:1797-1805.
10. Carney DN. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 1996; 23:71-75.
11. Khayat D, Antoine EC, Coeffic D. Taxol in the management of cancers of the breast and the ovary. Cancer Invest 2000; 18:242-260.
12. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332:1004-1014.
13. Smith R, Thornton D, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995; 22:41-46.
14. Forastiere AA, Shank D, Neuberg D, Taylor SG IV, Deconti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82:2270-2274.
15. Koukourakis MI, Bizakis JG, Skoulakis CE, Kyrmizakis D, Giatromanolaki A, Papadakis CE, et al. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 1999; 19:2305-2309.
16. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
17. Kloover JS, den Bakker MA, Gelderbolm H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004; 90:304-305.
18. Xie M, Zhou L, Hu T, Yao M. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts. Anticancer Drugs 2007; 18:459-466.
19. Feng SS. Nanoparticles of biodegradable polymers for new concept chemotherapy. Expert Rev Med Dev 2004; 1:115-125.
20. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998; 95:4607-4612.
21. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular-permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752-3756.
22. Sledge GW, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 2003; 39:1668-1675.
23. Teicher BA. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist Update 2000; 3:67-73.
24. Lu W, Wang J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 2007; 118:38-53.
25. Forastiere AA. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol 2008; 97:701-707.
26. Mooney DJ, Sano K, Kaufmann PM, Majahod K, Schloo B, Vacanti JP, et al. Long-term engraftment of hepatocytes transplanted on biodegradable polymer sponges. J Biomed Mater Res 1997; 37:413-420.
27. Dong YC, Feng SS. Methoxy poly (ethylene glycol)-poly (lactide) (MPEGPLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004; 25:2843-2849.
28. Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release 2002; 83:389-400.
29. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 2007; 338:317-326.
30. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J Control Release 2002; 80:129-144.
31. Zhang Z, Feng SS. Nanoparticles of poly (lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006; 27:262-270.
32. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 2007; 67:1-8.
33. Panyam J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly (D, L-lactideco- glycolide) nanoparticles. Int J Pharm 2003; 262:1-11.
34. Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000; 210:61-67.
35. Dong Y, Feng SS. In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide(MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials 2007; 28:4154-4160.
36. Pietzonka P, Rothen-Rutishauser B, Langguth P, Wunderli-Allenspach H, Walter E, Merkle HP. Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to CaCO-2 monolayers mimics particle uptake. Pharm Res 2002; 19:595-601.
37. Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, et al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol pharm 2009; 6:190-201.